Cytomyx Therapeutics
Clinical-stage biopharmaceutical company focused on oncology. Develops conditionally activated biologics using a tumor-activated antibody prodrug platform and advances multiple antibody-drug conjugate (ADC) candidates into early-phase clinical trials. Publishes technical content related to glycoproteomics, bioconjugation, antibody engineering, and analytical assay methods.
Industries
Nr. of Employees
medium (51-250)
Products
ADC candidate targeting NTSR1 (clinical candidate)
Antibody-drug conjugate designed to target neurotensin receptor-1 (NTSR1) for treatment of pancreatic cancer; progressed into phase 1/2 clinical evaluation.
ADC candidate targeting SSTR2 (clinical candidate)
Antibody-drug conjugate designed to target somatostatin receptor 2 (SSTR2) for treatment of pancreatic, gastric, and colon cancers; progressed into phase 1/2 clinical evaluation.
ADC candidate targeting PTH1R (clinical candidate)
Antibody-drug conjugate designed to target parathyroid hormone 1 receptor (PTH1R) for treatment of thyroid cancer; progressed into phase 1/2 clinical evaluation.
ADC candidate targeting NTSR1 (clinical candidate)
Antibody-drug conjugate designed to target neurotensin receptor-1 (NTSR1) for treatment of pancreatic cancer; progressed into phase 1/2 clinical evaluation.
ADC candidate targeting SSTR2 (clinical candidate)
Antibody-drug conjugate designed to target somatostatin receptor 2 (SSTR2) for treatment of pancreatic, gastric, and colon cancers; progressed into phase 1/2 clinical evaluation.
ADC candidate targeting PTH1R (clinical candidate)
Antibody-drug conjugate designed to target parathyroid hormone 1 receptor (PTH1R) for treatment of thyroid cancer; progressed into phase 1/2 clinical evaluation.
Expertise Areas
- Oncology drug development
- Conditionally activated biologics
- Antibody-drug conjugate development
- Antibody engineering and affinity maturation
Key Technologies
- Tumor-activated antibody prodrug platforms
- Antibody-drug conjugates (ADC)
- Mass spectrometry for glycoproteomics
- Glycan analysis
News & Updates
Article on quantitative PCR best practices, common failure modes, and troubleshooting strategies for molecular assays.
Discussion of antibody affinity maturation approaches and their relevance to therapeutic antibody development.
Overview of the role of glycoproteomics in drug discovery and its application to therapeutic development.
Article describing mass spectrometric analysis of glycosylation and its implications for bioconjugation and drug discovery.
Discussion of glycan biology and the potential for glycan-based therapeutic approaches.
Article on quantitative PCR best practices, common failure modes, and troubleshooting strategies for molecular assays.
Discussion of antibody affinity maturation approaches and their relevance to therapeutic antibody development.
Overview of the role of glycoproteomics in drug discovery and its application to therapeutic development.
Article describing mass spectrometric analysis of glycosylation and its implications for bioconjugation and drug discovery.
Discussion of glycan biology and the potential for glycan-based therapeutic approaches.